Key statistics
As of last trade Zai Lab Ltd (1ZLB:MUN) traded at 2.46, -19.61% below its 52-week high of 3.06, set on Nov 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.46 |
---|---|
High | 2.46 |
Low | 2.46 |
Bid | 2.32 |
Offer | 2.54 |
Previous close | 2.50 |
Average volume | 1.11k |
---|---|
Shares outstanding | 1.09bn |
Free float | 979.09m |
P/E (TTM) | -- |
Market cap | 22.27bn HKD |
EPS (TTM) | -2.16 HKD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:13 GMT.
More ▼
Press releases
- Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
- Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
- Zai Lab Announces Pricing of Public Offering of American Depositary Shares
- Zai Lab Announces Proposed Public Offering of American Depositary Shares
- Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
- Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
- Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
- ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
- Zai Lab Announces Participation in November and December Investor Conferences
- Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
More ▼